genentech up $11 billion, page-3

If the market cap of a pharam goes up by $11 billion with that news, it makes you wonder how valuable Solbec's Coramsine is at the moment. Although the drug has only completed phase I trials (compared with phase III), the promise the drug has shown in these early trials would have to make it be worth far more than $25mil. Hopefully with the new US connections and the ADR's, American investors who are willing to pour $11 billion into Genentech will think about putting some capital into this little Aussie biotech with just as much potential.